Abstract: The present disclosure relates to antibody conjugates with binding specificity for folate receptor alpha (FOLR1) and its isoforms and homologs, and compositions comprising the antibody conjugates, including pharmaceutical compositions. Also provided are methods of producing the antibody conjugates and compositions as well as methods of using the antibody conjugates and compositions, such as in therapeutic and diagnostic methods.

Abstract: Provided herein are antibodies that selectively bind to LAG3 and its isoforms and homologs, and compositions comprising the antibodies. Also provided herein are antibodies that selectively bind to PD-1 and its isoforms and homologs, and compositions comprising the antibodies. In addition, provided herein are bi-specific antibodies and antigen binding constructs that selectively bind to LAG3 and/or PD-1, their isoforms and homologs, and compositions comprising the antibodies and antigen binding constructs. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.

Abstract: Provided herein are antibodies that selectively bind to LAG3 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.

Abstract: The present disclosure relates to antibodies that selectively bind to folate receptor alpha (FOLR1) and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.

Abstract: Provided herein are antibody conjugates with binding specificity for CD74, wherein the antibody comprises a non-natural amino acid at a site selected from the group consisting of HC-F404, HC-K121, HC-Y180, HC-F241, HC-221, LC-T22, LC-S7, LC-N152, LC-K42, LC-E161, LC-D170, HC-S136, HC-525, HC-A40, HC-S119, HC-S190, HC-K222, HC-R19, HC-Y52, or HC-S70, according to the Kabat, Chothia, or EU numbering scheme, and compositions comprising the antibody conjugates, including pharmaceutical compositions, methods of producing the conjugates, and methods of using the conjugates and compositions for therapy.

Abstract: The present disclosure relates to antibody conjugates with binding specificity for folate receptor alpha (FOLR1) and its isoforms and homologs, and compositions comprising the antibody conjugates, including pharmaceutical compositions. Also provided are methods of producing the antibody conjugates and compositions as well as methods of using the antibody conjugates and compositions, such as in therapeutic and diagnostic methods.

Abstract: Provided herein are modified amino acids comprising an azido group, polypeptides, antibodies and conjugates comprising the modified amino acids, and methods of producing the polypeptides, antibodies and conjugates comprising the modified amino acids. The polypeptides, antibodies and conjugates are useful in methods of treatment and prevention, methods of detection and methods of diagnosis.

Abstract: Provided herein are antibodies that selectively bind to EpCAM and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.

Abstract: Provided herein are modified amino acids comprising an azido group, polypeptides, antibodies and conjugates comprising the modified amino acids, and methods of producing the polypeptides, antibodies and conjugates comprising the modified amino acids. The polypeptides, antibodies and conjugates are useful in methods of treatment and prevention, methods of detection and methods of diagnosis.

Abstract: Provided herein are modified amino acids comprising an azido group, polypeptides, antibodies and conjugates comprising the modified amino acids, and methods of producing the polypeptides, antibodies and conjugates comprising the modified amino acids. The polypeptides, antibodies and conjugates are useful in methods of treatment and prevention, methods of detection and methods of diagnosis.

Abstract: Methods and systems for increasing the stability of a nucleic acid template that encodes a protein of interest in a cell free translation system or a ribosomal display reaction system are described. In some embodiments, the nucleic acid template is an RNA or mRNA. The stability of the RNA template is increased by adding the bacteriophage lambda protein Gam to the cell free extract used in the translation system. The addition of Gam protein increases the longevity of the reaction system, thereby increasing the efficiency of the ribosomal display reaction system.

Abstract: Provided herein are antibodies that selectively bind to PD-1 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.

Abstract: Methods and systems for increasing the stability of a nucleic acid template that encodes a protein of interest in a cell free translation system or a ribosomal display reaction system are described. In some embodiments, the nucleic acid template is an RNA or mRNA. The stability of the RNA template is increased by adding the bacteriophage lambda protein Gam to the cell free extract used in the translation system. The addition of Gam protein increases the longevity of the reaction system, thereby increasing the efficiency of the ribosomal display reaction system.

Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to human CD47. Also provided are uses and methods, such as therapeutic methods, diagnostic methods, and methods of making such antibodies.

Abstract: Provided herein are modified amino acids comprising an azido group, polypeptides, antibodies and conjugates comprising the modified amino acids, and methods of producing the polypeptides, antibodies and conjugates comprising the modified amino acids. The polypeptides, antibodies and conjugates are useful in methods of treatment and prevention, methods of detection and methods of diagnosis.

Abstract: Provided herein are modified amino acids comprising an azido group, polypeptides, antibodies and conjugates comprising the modified amino acids, and methods of producing the polypeptides, antibodies and conjugates comprising the modified amino acids. The polypeptides, antibodies and conjugates are useful in methods of treatment and prevention, methods of detection and methods of diagnosis.

Abstract: Provided herein are antibodies that selectively bind to CD74 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.

Abstract: Provided herein are modified amino acids comprising an azido group, polypeptides, antibodies and conjugates comprising the modified amino acids, and methods of producing the polypeptides, antibodies and conjugates comprising the modified amino acids. The polypeptides, antibodies and conjugates are useful in methods of treatment and prevention, methods of detection and methods of diagnosis.

Abstract: The invention relates to a method for generating and selecting Fab fragments using ribosomal display and cell-free protein synthesis. The invention also provides a ribosomal display reaction system for generating Fab fragment complexes. The compositions of a Fab fragment complex and a library thereof are also provided.

Abstract: Methods and systems for increasing the stability of a nucleic acid template that encodes a protein of interest in a cell free translation system or a ribosomal display reaction system are described. In some embodiments, the nucleic acid template is an RNA or mRNA. The stability of the RNA template is increased by adding the bacteriophage lambda protein Gam to the cell free extract used in the transalation system. The addition of Gam protein increases the longevity of the reaction system, thereby increasing the efficiency of the ribosomal display reaction system.